A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach.

Mulder, Jorn; van Stuijvenberg, Odile C; van Hennik, Paula B; Voest, Emile E; Pasmooij, Anna M G; Stoyanova-Beninska, Violeta; de Boer, Anthonius

Mulder, Jorn; van Stuijvenberg, Odile C; van Hennik, Paula B; Voest, Emile E; Pasmooij, Anna M G; Stoyanova-Beninska, Violeta; de Boer, Anthonius.

Afiliação

Mulder J; Dutch Medicines Evaluation Board, Utrecht, Netherlands.
van Stuijvenberg OC; Dutch Medicines Evaluation Board, Utrecht, Netherlands.
van Hennik PB; Dutch Medicines Evaluation Board, Utrecht, Netherlands.
Voest EE; The Netherlands Cancer Institute, Amsterdam, Netherlands.
Pasmooij AMG; Oncode Institute, Amsterdam, Netherlands.
Stoyanova-Beninska V; Dutch Medicines Evaluation Board, Utrecht, Netherlands.
de Boer A; Dutch Medicines Evaluation Board, Utrecht, Netherlands.

Front Med (Lausanne) ; 9: 893400, 2022.

Article em En | MEDLINE | ID: mdl-35775007

Palavras-chave

EMA; FDA; PMDA; post-marketing measures; tissue-agnostic indication

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article